Michael B Fisher

Summary

Publications

  1. ncbi The role of the intestine in drug metabolism and pharmacokinetics: an industry perspective
    Michael B Fisher
    Cara Therapeutics, Tarrytown, NY 10591, USA
    Curr Drug Metab 8:694-9. 2007
  2. ncbi Characterization by liquid chromatography-nuclear magnetic resonance spectroscopy and liquid chromatography-mass spectrometry of two coupled oxidative-conjugative metabolic pathways for 7-ethoxycoumarin in human liver microsomes treated with alamethicin
    Michael B Fisher
    Department of Drug Disposition, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    Drug Metab Dispos 30:270-5. 2002
  3. ncbi Flavin-containing monooxygenase activity in hepatocytes and microsomes: in vitro characterization and in vivo scaling of benzydamine clearance
    Michael B Fisher
    Discovery Pharmacokinetics, Dynamics and Metabolism, Pfizer Global Research and Development, Pfizer Inc, Eastern Point Rd, Groton, Connecticut 06340, USA
    Drug Metab Dispos 30:1087-93. 2002
  4. ncbi A streamlined method to predict hepatic clearance using human liver microsomes in the presence of human plasma
    Sara M Skaggs
    Pfizer Global Research and Development, Pharmacokinetics, Dynamics, and Metabolism Pfizer, Inc. Groton, CT 06340, USA
    J Pharmacol Toxicol Methods 53:284-90. 2006
  5. ncbi The complexities inherent in attempts to decrease drug clearance by blocking sites of CYP-mediated metabolism
    Michael B Fisher
    Boehringer Ingelheim Pharmaceuticals Inc, 900 Ridgebury Road, Ridgefield, CT 06877, USA
    Curr Opin Drug Discov Devel 9:101-9. 2006
  6. ncbi In vivo use of the P450 inactivator 1-aminobenzotriazole in the rat: varied dosing route to elucidate gut and liver contributions to first-pass and systemic clearance
    Timothy J Strelevitz
    Pfizer Inc, PGRD, Pharmacokinetics, Dynamics, and Metabolism, Eastern Point Road, Groton, CT 06340, USA
    J Pharm Sci 95:1334-41. 2006
  7. ncbi Recent advances in high throughput screening for ADME properties
    Timothy J Carlson
    Amgen Inc, 1120 Veterans Boulevard, South San Francisco, CA 94080, USA
    Comb Chem High Throughput Screen 11:258-64. 2008

Collaborators

  • Timothy J Carlson
  • Robert S Foti
  • Sara M Skaggs
  • Timothy J Strelevitz

Detail Information

Publications7

  1. ncbi The role of the intestine in drug metabolism and pharmacokinetics: an industry perspective
    Michael B Fisher
    Cara Therapeutics, Tarrytown, NY 10591, USA
    Curr Drug Metab 8:694-9. 2007
    ..The opportunity exists to increase the examination of intestinal metabolism of drugs and drug candidates in industry...
  2. ncbi Characterization by liquid chromatography-nuclear magnetic resonance spectroscopy and liquid chromatography-mass spectrometry of two coupled oxidative-conjugative metabolic pathways for 7-ethoxycoumarin in human liver microsomes treated with alamethicin
    Michael B Fisher
    Department of Drug Disposition, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    Drug Metab Dispos 30:270-5. 2002
    ..Viewed collectively, these results illustrate the utility of alamethicin in the examination of coupled oxidative-conjugative metabolism and the synergy of LC-NMR and LC-MS in metabolite identification...
  3. ncbi Flavin-containing monooxygenase activity in hepatocytes and microsomes: in vitro characterization and in vivo scaling of benzydamine clearance
    Michael B Fisher
    Discovery Pharmacokinetics, Dynamics and Metabolism, Pfizer Global Research and Development, Pfizer Inc, Eastern Point Rd, Groton, Connecticut 06340, USA
    Drug Metab Dispos 30:1087-93. 2002
    ..Benzydamine N-oxidation in liver microsomes from all common preclinical species demonstrated heat sensitivity. This information should be considered when extrapolating metabolism data of xenobiotics from these in vitro systems...
  4. ncbi A streamlined method to predict hepatic clearance using human liver microsomes in the presence of human plasma
    Sara M Skaggs
    Pfizer Global Research and Development, Pharmacokinetics, Dynamics, and Metabolism Pfizer, Inc. Groton, CT 06340, USA
    J Pharmacol Toxicol Methods 53:284-90. 2006
    ....
  5. ncbi The complexities inherent in attempts to decrease drug clearance by blocking sites of CYP-mediated metabolism
    Michael B Fisher
    Boehringer Ingelheim Pharmaceuticals Inc, 900 Ridgebury Road, Ridgefield, CT 06877, USA
    Curr Opin Drug Discov Devel 9:101-9. 2006
    ..The concepts and evidence behind this phenomenon as it relates to complexities in blocking metabolic clearance are presented herein...
  6. ncbi In vivo use of the P450 inactivator 1-aminobenzotriazole in the rat: varied dosing route to elucidate gut and liver contributions to first-pass and systemic clearance
    Timothy J Strelevitz
    Pfizer Inc, PGRD, Pharmacokinetics, Dynamics, and Metabolism, Eastern Point Road, Groton, CT 06340, USA
    J Pharm Sci 95:1334-41. 2006
    ..This method should have utility in drug discovery for the identification of factors limiting oral bioavailability...
  7. ncbi Recent advances in high throughput screening for ADME properties
    Timothy J Carlson
    Amgen Inc, 1120 Veterans Boulevard, South San Francisco, CA 94080, USA
    Comb Chem High Throughput Screen 11:258-64. 2008
    ..Future advances will further improve the ability to make decisions on molecules earlier in drug discovery...